 |
 |
 |
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Drug Portfolio
The following table lists the relative priority of development of drugs in Phage’s portfolio.
Product |
Medical Indication |
Stage of Development |
1. Human growth hormone |
Short stature in children |
Pivotal Clinical Trial Designed (Phase III) |
2. PEG-Interferon alpha 2b |
Anti-viral, anti-cancer |
Phase I Clinical Trial Submitted to FDA |
3. PEG-Human growth hormone |
Short stature |
Pre-clinical completed, Animal Toxicity Planned |
4. Beta-interferon |
Multiple sclerosis |
Pre-clinical ongoing |
5. Peg-G-CSF |
Chemotherapy side effects |
Pre-clinical completed, Animal Toxicity Planned |
Contract Manufacturing
The following table shows Phage’s contract manufacturing drug that has been manufactured in our facility in California, and which is in U.S. clinical trials (Phase II trials).
Product |
Medical Indication |
1. Human Fibroblast Growth Factor (FGF-1) |
Severe Coronary Artery Disease; Diabetic Wound Healing Disorders; Peripheral Artery Disease; Cerebrovascular Diseases; Vertebral Disc Ischemia; Bone Repair. |
Home | Contact Us |
Webmaster
©2008 Phage Biotechnology Corp. All Rights Reserved